This lecture was conducted during the Nephrology Unit Grand Ground by Consultant under Nephrology Division under the supervision and administration of.

Slides:



Advertisements
Similar presentations
LINEE GUIDA, KDIGO E DIALISI PERITONEALE
Advertisements

MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE PEDRAM.AHMADPOOR SHAHID BEHESHTI MEDICAL UNIVERSITY.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Mario Cozzolino, MD, PhD NUOVE ACQUISIZIONI NELLA TERAPIA DELL’IPERPARATIROIDISMO SECONDARIO IN DIALISI PERITONEALE XV CONVEGNO del Gruppo di Studio di.
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
Dr Annie NK Chiu United Christian Hospital Joint Hospital Surgical Grand Round 20 th Apr 2013.
Dr Guy ANDRY, M. MOREAU, I.EL MOUSSAOUI, E. WILLEMSE, M. QUIRINY, A. DIGONNET Université Libre de Bruxelles, Brussels.
Nephrology Grand Rounds 5/13/08. Refractory Hyperparathyroidism Brad Weaver.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
UK Renal Registry 17th Annual Report Figure 8.1. Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
Calcium Disorders Dr. Sohail Inam Consultant Endocrine & Diabetes Prince Sultan Military Medical City Riyadh.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
HYPOCALCEMIA MBBS 2011 BATCH 06/08/14. CALCIUM Total body calcium content- 1-2 kg 99% of it is within the bone in the form of hydroxyapatite It is present.
Diseases of the Renal System KNH 413. CKD - Renal Replacement Therapy Hemodialysis (HD) or Peritoneal Dialysis (PD) Type based on underlying kidney disease.
Calcium & phosphorus.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
CKD Creatinine clearance - Cockroft- Gault formula (140-age) x body mass (kg) Serum creatinine concentration x 72 Female x coefficient 0.85.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
HYPOCALCEMIA Management in the Post-Op and Chronic Setting Donna Mojdami, PGY-2 Internal Medicine.
UK Renal Registry 9 th Annual Report 2006 Fig 9.1 Percentage of patients with serum phosphate
Biochemical Test Serum Calcium
Tertiary hyperparathyroidism & postoperative hypocalcemia Brock Lanier, M.D. MCV/VCU Department of Surgery M&M 12 April
Assessment and management of parathyroid hyperplasia in secondary hyperparathyroidism Mario Meola, MD, PhD University of Pisa, Hospital of Cisanello, Pisa,
Chronic Kidney Disease SERVICE 6. Chronic Kidney Disease Stages 4-5 (GFR
New NKF-K/DOQI guidelines Shahrzad Ossareh-M.D. Kidney Disease Outcome Quality Initiative.
+ This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Diagnostic and Therapeutic Approach to Kidney Patient S. Ossareh- M.D. HKC-IUMS S. Ossareh- M.D. HKC-IUMS.
Home Haemodialysis in Wales An Evaluation of Nutritional Needs Harriet Williams Clinical Dietitian - Renal Lead, BCU.
UK Renal Registry 16th Annual Report Figure Percentage of haemodialysis patients with phosphate within the range specified by the RA clinical audit.
CHAPTER 9: Chronic Kidney Disease – Mineral and Bone DisorderKok Lai Sun Ching Chen Hua Fan Kin Sing Rozina Ghazalli Liew Yew Fong Source: 21 st MDTR Report.
Consensus procedure for the management of children with ESRD.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Primary Hyperparathyroidism presenting with Pancreatitis Prof. Aasem Saif MD, MRCP(UK), FRCP(Edin) Workshop A (Calcium and Bone) Friday 25 October 2013.
Hypercalcemia A diagnostic and treatment approach UCI Internal Medicine – Mini Lecture.
Hypercalcemia A diagnostic and treatment approach UCI Internal Medicine – Mini Lecture.
What we are missing 2012 KDIGO guideline. Anemia.
Oral Phosphate Binders in Patients with Kidney Failure
Hungry bone syndrome following parathyroidectomy
Skeletal Physiology: Fetus and Neonate
UK Renal Registry 18th Annual Report
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Department of Nephrology- Ain Shams University, Cairo, Egypt
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
The ECHO Observational Study
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
HYPERPHOSPHAT EMIA Group 5. Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology.
Thadhani et al. Am J Nephrol 2017;45:40-48  (DOI: / )
Bone metabolism and disease in chronic kidney disease
Furosemide-Induced Severe Hypocalcemia in Latent Hypoparathyroidism
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
CHAPTER 9 Chronic Kidney Disease – Mineral and Bone Disorder
Volume 65, Issue 5, Pages (May 2004)
Severe Hypocalcemia after total parathyroidectomy plus autotransplantation for secondary hyperparathyroidism-risk factors and management 周逢復1 黃純真2 陳靖博3.
Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study  Wajeh Y. Qunibi, Charles.
Volume 79, Issue 1, Pages (January 2011)
Volume 74, Pages S88-S93 (December 2008)
Diseases of the Renal System
Diseases of the Renal System
James A. Sloand, MD, Mark A. Shelly, MD 
Perioperative considerations for parathyroidectomy in patients on dialysis. Perioperative considerations for parathyroidectomy in patients on dialysis.
Presentation transcript:

This lecture was conducted during the Nephrology Unit Grand Ground by Consultant under Nephrology Division under the supervision and administration of Prof. Jamal Al Wakeel, Head of Nephrology Unit, Department of Medicine and Dr. Abdulkareem Al Suwaida, Chairman of the Department of Medicine. Nephrology Division is not responsible for the content of the presentation for it is intended for learning and /or education purpose only.

CaCO3 & CALCITRIOL PROTOCOL IN HD Presented by: Dr Faraz Niaz Consultant May 2008

CALCIUM Evaluation Monthly Daily intake should not be > 2000 mg/day (eg 1500 from P-binders & 500 from diet ) Target: Low normal preferred : 2.1 – 2.4 mmol/L (corrected (8.4 – 9.5 mg/dl) If > 2.55 mol/L(10.2mg/dl), change to Non-Ca binders, ↓ Vit D or change to low Ca-dialysate

PHOSPHORUS Evaluation Monthly Daily intake (adjusted to protein intake) 800 – 1000mg/day Phosphate/ gram of protein : 12 – 16 mg. Target mmol/L (3.5 – 5.5 mg/dl)

PHOSPHATE BINDERS Start when P or PTH > Target Use CaCO3 or/and non-Ca binder(Sevelamer Limit Ca intake from binders to 1500mg/day. 1.CaCO3 upto 600 mg BD with food 2.Sevelamer (Renagel) 800 mg with meals(↑upto 2 tab TID Stop Ca-binder if Ca >2.55 mmol/L or PTH < 15 Aluminum binder may be used for short term (up to 4 wks) if P >2.33 ( 7.0 mg/dl), &for one course. In such pt, consider more frequent dialysis.

iPTH PTH Target 16 – 33 pmol/L ( pg/ml) Evaluation Every 3 Months

Vitamin D (Calcitriol) Start if PTH > 33 pmol/L ( 300 pg/ml) Ca < 2.4 mmol/l ( 6.5 mg/dl) P < 1.8 mmol/l ( 5.5 mg/dl) Ca x P < 4.4 ( 55 mg/dl²) Hold Calcitriol:when PTH < 15 pmol/L(150 pglml) Ca > 2.55 mmol/L (10.2 mg/dl) P > 1.8 mmol/L (1.8 pg/dl)

When to change the dose of Calcitriol If decrease in PTH is > 50% after 4 wks of initiation, then decrease dose to half. If Calcitriol was held as PTH had decreased to 33

Normal physiological dose 1µg/day

IV Dose Regimens: Calcitriol can be started at dose of 0.5 µg & titrated upward to 2.0 µg at end of each HD depending upon PTH levels. Dose of Calcitriol should be titrated to raise Ca level to approx 2.4 – 2.55mmol/L( ). NOTE: Total Ca should be ↑ to levels required to suppress PTH to desired levels while avoiding hypercalcemia. Calcitriol dose should be reduced by 50% or stopped with Ca levels at the upper normal range or with mild hypercalcemia ( 2.5 – 2.63mmol/L) ( mg/dl). D/C Calcitriol for frank hypercalcemia ( >2.63mmol/L) or 10.5mg/dl) After resolution of hypercalcemia restart Calcitriol

PTH pmol/L Dose/ HD of Calcitriol 33 – 60 Oral / IV: 0.5 – 1.5 µg 60 – 100 Oral:1– 4 µg & IV:1 – 3 µg > 100 Oral:3 – 7µg &IV: 3 – 5µg

PD pts may receive Oral Calcitriol 0.5 – 1.0 µg 2 to 3 times/week. A lower dose of 0.25 mcg may be given daily

Indications for Parathyroidectomy by DOQI Severe hyperparathyroidism refractory to medical therapy 1. PTH >800 pmol/l (88 pg/ml) &/or ↑ Ca & > ↑ P 2. Calciphylaxis with PTH > 500pmol/L ( 55pg/ml )

Other Indications for Parathyroidectomy Intractable pruritis with ↑ PTH Recurrent need of with holding Vit D due to ↑ Ca or P Gland size by USD or CT Scan 0.5 cm or volume >0.5 cm

DOQI recommends Pre-op parathyroid imaging (USD, CT, MRI, MIBI Scan) is usually not required, but may be used if recurrent hyperparathyroidism

POST- Parathyroidectomy protocol Measure Ca every 4 – 6 hrs for 48 to 72 hrs. If ionized Ca is <0.9 mmol/L (3.6 mg/dl) or Corrected Ca <1.8 mmol/L(7.2) Start Ca infusion 1 – 2 mg/kg/hr. of elemental Ca (10 ampoules of 10% calcium gluconate (10ml each) contain 90 mg of elemental Ca) Decrease Ca infusion gradually when ionized Ca is normal & stable. Oral CaCO3 can be 1- 2 Gm TID + + Calcitriol upto 2 µg/day Adjust these to keep ionized Ca in normal range of 1.16 – 1.32 mmol/L ( mg/dl)